Redeye provides a research update following the Q4 report recently published by Magle. The company reported a higher sales figure than expected, a 25% y/y growth, bolstered by increased revenue from its DSM products. While OPEX and COGS were slightly above our expectations, this still resulted in a higher EBIT than expected. Overall, we are encouraged by the company’s Q4 report. We reiterate our previous fair value range (SEK25 – SEK58) with a base case valuation of SEK40 as we continue to have a positive outlook on the case.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Magle Chemoswed Q4 - Ramp up in sales

© Modular Finance, source Nordic Press Releases